CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
CytoDyn (OTCQB: CYDY), a clinical-stage oncology company, will present research findings on its lead drug leronlimab at the AACR Special Conference on Cancer Immunity from September 24-27, 2025, in Montreal. The company's Lead Consultant, Dr. Richard Pestell, will deliver both poster and oral presentations focusing on leronlimab's effects on metastatic triple-negative breast cancer (TNBC).
The research suggests that leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, may convert 'cold' tumors to 'hot' tumors, potentially enhancing responsiveness to checkpoint inhibitors. This mechanism could have broad implications for treating solid tumors with limited treatment options.
CytoDyn (OTCQB: CYDY), un’azienda oncologica in fase clinica, presenterà risultati sul suo lead leronlimab all’AACR Special Conference on Cancer Immunity dal 24 al 27 settembre 2025 a Montréal. Il Lead Consultant dell’azienda, il Dottor Richard Pestell, terrà presentazioni sia in poster sia orali che riguardano gli effetti di leronlimab sul cancro metastatico al seno triple-negativo (TNBC).
La ricerca suggerisce che leronlimab, un anticorpo monoclonale umano di prima classe che prende di mira il recettore CCR5, potrebbe trasformare i tumori ‘freddi’ in tumori ‘caldi’, migliorando potenzialmente la risposta agli inibitori dei checkpoint. Questo meccanismo potrebbe avere ampie implicazioni per il trattamento di tumori solidi con opzioni terapeutiche limitate.
CytoDyn (OTCQB: CYDY), una empresa oncológica en etapa clínica, presentará hallazgos sobre su fármaco líder leronlimab en la AACR Special Conference on Cancer Immunity del 24 al 27 de septiembre de 2025 en Montreal. El asesor principal de la empresa, el Dr. Richard Pestell, ofrecerá presentaciones en póster y orales centradas en los efectos de leronlimab sobre el cáncer de mama metastásico triple negativo (TNBC).
La investigación sugiere que leronlimab, un anticuerpo monoclonal humano de primera clase dirigido al receptor CCR5, podría convertir tumores 'fríos' en tumores 'calientes', lo que podría aumentar la respuesta a los inhibidores de puntos de control. Este mecanismo podría tener implicaciones amplias para el tratamiento de tumores sólidos con opciones limitadas.
CytoDyn(OTCQB: CYDY)는 임상 단계의 종양학 기업으로, 주력 약물 leronlimab에 대한 연구 결과를 2025년 9월 24일부터 27일까지 몬트리올에서 열리는 AACR Special Conference on Cancer Immunity에서 발표합니다. 회사의 수석 컨설턴트 Dr. Richard Pestell 박사는 TNBC(전이된 삼중음성 유방암)에 대한 leronlimab의 효과를 다루는 포스터와 구두 발표를 모두 진행합니다.
연구에 따르면 CCR5 수용체를 표적으로 하는 1세대 인간화 단일클론항체인 leronlimab은 '차가운' 종양을 '뜨거운' 종양으로 전환시켜 면역 체크포인트 억제제에 대한 반응을 높일 수 있을 가능성이 있습니다. 이 기전은 치료 옵션이 제한된 고형 종양의 치료에 광범위한 시사점을 가질 수 있습니다.
CytoDyn (OTCQB: CYDY), une société en oncologie en phase clinique, présentera des résultats sur son médicament phare leronlimab lors de la AACR Special Conference on Cancer Immunity du 24 au 27 septembre 2025 à Montréal. Le consultant principal de l’entreprise, le Dr. Richard Pestell, effectuera des présentations poster et orales axées sur les effets de leronlimab sur le cancer du sein triple négatif métastatique (TNBC).
Les recherches suggèrent que leronlimab, un anticorps monoclonal humain de première classe ciblant le récepteur CCR5, pourrait transformer les tumeurs « froides » en tumeurs « chaudes », améliorant potentiellement la réactivité aux inhibiteurs de points de contrôle. Ce mécanisme pourrait avoir des répercussions importantes pour le traitement des tumeurs solides avec des options limitées.
CytoDyn (OTCQB: CYDY), ein im klinischen Stadium befindliches Onkologie-Unternehmen, wird Forschungsergebnisse zu seinem Leitmedikament Leronlimab bei der AACR Special Conference on Cancer Immunity vom 24. bis 27. September 2025 in Montréal präsentieren. Der Lead Consultant des Unternehmens, Dr. Richard Pestell, wird sowohl Poster- als auch Vortragspräsentationen halten, die sich auf die Auswirkungen von LerONlimab auf metastasiertes Triple-negatives Brustkrebs (TNBC) konzentrieren.
Die Forschung legt nahe, dass Ler onlimab, ein erstklassiger, humanisierter monoklonaler Antikörper, der auf den CCR5-Rezeptor abzielt, Tumoren von ‚kalt‘ zu ‚heiß‘ machen könnte, wodurch möglicherweise die Reaktion auf Checkpoint-Inhibitoren verbessert wird. Dieser Mechanismus könnte weitreichende Implikationen für die Behandlung solider Tumore mit begrenzten Therapiewegen haben.
سيتي-دون (OTCQB: CYDY)، شركة في طور التجربة الإكلينيكية في مجال الأورام، ستعرض نتائج أبحاث عن دوائها الرائد leronlimab في AACR Special Conference on Cancer Immunity من 24 إلى 27 سبتمبر 2025 في مونتريال. سيقدم المستشار الرئيسي للشركة الدكتور ريتشارد بيستل عروضاً مميزة ومساقات شفوية تركز على تأثير leronlimab على سرطان الثدي الثلاثي السلبي metastatic (TNBC).
تشير الأبحاث إلى أن leronlimab، وهو جسم مضاد أحادي النسيلة بشري من الدرجة الأولى يستهدف مستقبل CCR5، قد يحوّل الأورام «الباردة» إلى أورام «الساخنة»، مما قد يعزز الاستجابة لمثبطات نقاط التفتيش. يمكن أن تكون لهذه الآلية تبعات واسعة في علاج الأورام الصلبة ذات الخيارات المحدودة.
CytoDyn (OTCQB: CYDY)，一家处于临床阶段的肿瘤学公司，将在2025年9月24日至27日于蒙特利尔举行的AACR Special Conference on Cancer Immunity上展示其领先药物 leronlimab 的研究结果。公司的首席顾问Dr. Richard Pestell将进行海报及口头报告，聚焦 leronlimab 对转移性三阴性乳腺癌（TNBC）的作用。
研究表明，leronlimab 作为第一类人源化单克隆抗体，靶向 CCR5 受体，可能将“冷”肿瘤转变为“热”肿瘤，从而提高对检查点抑制剂的反应性。这一机制可能对治疗选择有限的实体瘤具有广泛影响。
- None.
- None.
VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced it has been selected for a poster and an oral presentation at the upcoming AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity, taking place September 24 to 27, 2025, in Montreal, Canada.
Richard Pestell, M.D., Ph.D., FRCP, AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn, will deliver a podium presentation on the effects of leronlimab on metastatic triple-negative breast cancer.
“We are encouraged by these findings, which suggest that leronlimab may convert ‘cold’ tumors into ‘hot’ ones, making them more responsive to checkpoint inhibitors in diseases like metastatic triple-negative breast cancer, an aggressive disease with substantial unmet need,” said Dr. Pestell, “The results of this research will also help to shed light on an underlying mechanism of action for leronlimab with potential broad applicability for solid tumors with limited treatment options.”
Details of the oral and poster presentations are as follows:
Abstract Title:
CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long‑term survival in metastatic TNBC
Presenter:
Richard Pestell, M.D., Ph.D., FRCP AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn
Poster presentation:
September 26, 2025, 6:30 p.m. – 8:30 p.m. EDT
Podium/speaking presentation:
September 27, 2025, 10:25 a.m. – 10:40 a.m. EDT
About CytoDyn
CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements relating to, among other things, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.
Corporate Contact
CytoDyn Inc.
ir@cytodyn.com
Media Contacts
Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com
FAQ
When will CytoDyn present at the AACR Special Conference 2025?
What is CytoDyn's leronlimab drug designed to treat?
Who will present CytoDyn's research at the AACR conference?
What are the key findings of CytoDyn's leronlimab research?
